Literature DB >> 22245190

Craniocaudal safety margin calculation based on interfractional changes in tumor motion in lung SBRT assessed with an EPID in cine mode.

Yoshihiro Ueda1, Masayoshi Miyazaki, Kinji Nishiyama, Osamu Suzuki, Katsutomo Tsujii, Ken Miyagi.   

Abstract

PURPOSE: To evaluate setup error and interfractional changes in tumor motion magnitude using an electric portal imaging device in cine mode (EPID cine) during the course of stereotactic body radiation therapy (SBRT) for non-small-cell lung cancer (NSCLC) and to calculate margins to compensate for these variations.
MATERIALS AND METHODS: Subjects were 28 patients with Stage I NSCLC who underwent SBRT. Respiratory-correlated four-dimensional computed tomography (4D-CT) at simulation was binned into 10 respiratory phases, which provided average intensity projection CT data sets (AIP). On 4D-CT, peak-to-peak motion of the tumor (M-4DCT) in the craniocaudal direction was assessed and the tumor center (mean tumor position [MTP]) of the AIP (MTP-4DCT) was determined. At treatment, the tumor on cone beam CT was registered to that on AIP for patient setup. During three sessions of irradiation, peak-to-peak motion of the tumor (M-cine) and the mean tumor position (MTP-cine) were obtained using EPID cine and in-house software. Based on changes in tumor motion magnitude (∆M) and patient setup error (∆MTP), defined as differences between M-4DCT and M-cine and between MTP-4DCT and MTP-cine, a margin to compensate for these variations was calculated with Stroom's formula.
RESULTS: The means (±standard deviation: SD) of M-4DCT and M-cine were 3.1 (±3.4) and 4.0 (±3.6) mm, respectively. The means (±SD) of ∆M and ∆MTP were 0.9 (±1.3) and 0.2 (±2.4) mm, respectively. Internal target volume-planning target volume (ITV-PTV) margins to compensate for ∆M, ∆MTP, and both combined were 3.7, 5.2, and 6.4 mm, respectively.
CONCLUSION: EPID cine is a useful modality for assessing interfractional variations of tumor motion. The ITV-PTV margins to compensate for these variations can be calculated.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245190     DOI: 10.1016/j.ijrobp.2011.07.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Asymmetric margin setting at the cranial and caudal sides in respiratory gated and non-gated stereotactic body radiotherapy for lung cancer.

Authors:  Yoshihiro Ueda; Shingo Oohira; Masaru Isono; Masayoshi Miyazaki; Teruki Teshima
Journal:  Br J Radiol       Date:  2015-12-23       Impact factor: 3.039

2.  Evaluation of two-dimensional electronic portal imaging device using integrated images during volumetric modulated arc therapy for prostate cancer.

Authors:  Shoki Inui; Yoshihiro Ueda; Shunsuke Ono; Shingo Ohira; Masaru Isono; Yuya Nitta; Hikari Ueda; Masayoshi Miyazaki; Masahiko Koizumi; Teruki Teshima
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

3.  Clinical translation of a new flat-panel detector for beam's-eye-view imaging.

Authors:  T C Harris; J Seco; D Ferguson; M Lehmann; P Huber; M Shi; M Jacobson; I Valencia Lozano; M Myronakis; P Baturin; R Fueglistaller; D Morf; R Berbeco
Journal:  Phys Med Biol       Date:  2020-12-07       Impact factor: 4.174

4.  Respiratory gating during stereotactic body radiotherapy for lung cancer reduces tumor position variability.

Authors:  Tetsuo Saito; Tomohiko Matsuyama; Ryo Toya; Yoshiyuki Fukugawa; Takamasa Toyofuku; Akiko Semba; Natsuo Oya
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

5.  4DCT and CBCT based PTV margin in Stereotactic Body Radiotherapy(SBRT) of non-small cell lung tumor adhered to chest wall or diaphragm.

Authors:  Yi Li; Jing-Lu Ma; Xin Chen; Feng-Wen Tang; Xiao-Zhi Zhang
Journal:  Radiat Oncol       Date:  2016-11-15       Impact factor: 3.481

6.  Using 4DCBCT simulation and guidance to evaluate inter-fractional tumor variance during SABR for lung tumor within the lower lobe.

Authors:  Yi Li; Wenjing Wu; Ruixin He; Yongkai Lu; Yuemei Zhang; Long Wang; Xiaozhi Zhang
Journal:  Sci Rep       Date:  2021-10-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.